Epixis' hep C vaccine shows early promise

French biotech company Epixis says it's used its experimental hepatitis C vaccine to fight off a variety of hepatitis C viruses in animal trials by spawning neutralizing antibodies. The developer is being purchased by an undisclosed U.S. company. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.